Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Ian Morrison, a highly regarded author, consultant and futurist, died last week. He specialized in long-term forecasting and planning with a particular emphasis on health care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback